✦ LIBER ✦

PHASE II STUDY OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN COMBINATION WITH IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA PATIENTS WITH ABNORMAL COAGULATION

✍ Scribed by L. Demidov; I. Tsimafeyeu; A. Madzhuga

Book ID: 119619274
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 71 KB
Volume: 7
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(08)60943-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PO-53 Phase II study of low molecular we

PO-53 Phase II study of low molecular weight heparin (LMWH) in combination with immunotherapy in metastatic renal cell carcinoma patients

✍ I. Tsimafeyeu; A. Madzhuga; L. Demidov; O. Somonova; A. Yelizarova 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Phase II study of lenalidomide in patien

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

✍ Toni K. Choueiri; Robert Dreicer; Brian I. Rini; Paul Elson; Jorge A. Garcia; Sn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 1 views

Phase I/II study of thalidomide in combi

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma

✍ Robert J. Amato; Margaret Morgan; Anish Rawat 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Phase II study of capecitabine single-ag

Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma

✍ Lance C. Pagliaro; Cherie A. Perez; Shi-Ming Tu; Danai D. Daliani 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 95 KB

A phase II study of vinblastine in combi

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma

✍ Jordan Berlin; A. Christie King; Kendra Tutsch; John W. Findlay; Peter Kohler; M 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 447 KB

Granulocyte-macrophage–colony stimulatin

Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f